Felicitas Kühne

Dr. Felicitas Kühne


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2024 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
ATAn Ta
An Ta
FKFelicitas Kühne
Felicitas Kühne
MLMaren Laurenz
Maren Laurenz
CEChristof von Eiff
Christof von Eiff
SWSophie Warren
Sophie Warren
JPJohnna Perdrizet
Johnna Perdrizet
Introduction Since 2009, a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) has been included by Germany’s Standing Committee on Vaccinations for infants, resulting in major reductions in pneumococcal disease (PD). Higher-valent vaccines may further reduce PD burden. This cost-effectiveness analysis compared 20-valent PCV (PCV20) under a 3+1 schedule with 15-valent PCV (PCV15) and PCV13, both under 2+1 schedule, in Germany’s pediatric population. Methods A Markov model with annual cycles over a 10-year time horizon was adapted to simulate the clinical and economic impact of pediatric vaccination with PCV20 versus lower-valent PCVs in Germany. The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for vaccine direct and indirect effect estimates. Epidemiologic, utility, and medical cost inputs were obtained from published sources. Benefits and costs were discounted at 3% from a German societal perspective. Outcomes included PD cases, deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results In the base case, PCV20 provided greater health benefits than PCV13, averting more cases of invasive pneumococcal disease (IPD; 15,301), hospitalized and non-hospitalized pneumonia (460,197 and 472,365, respectively), otitis media (531,634), and 59,265 deaths over 10 years. This resulted in 904,854 additional QALYs and a total cost saving of €2,393,263,611, making PCV20 a dominant strategy compared with PCV13. Compared to PCV15, PCV20 was estimated to avert an additional 11,334 IPD, 704,948 pneumonia, and 441,643 otitis media cases, as well as 41,596 deaths. PCV20 was associated with a higher QALY gain and lower cost (i.e., dominance) compared with PCV15. The robustness of the results was confirmed through scenario analyses as well as deterministic and probabilistic sensitivity analyses. Conclusion PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over 10 years. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20’s broader serotype coverage.

1 January 2025 in Health & Social Care in the Community
Verified
Journal Article
Open access
URUrsula Rochau
Ursula Rochau
VPVeronika Papon
Veronika Papon
ISIgor Stojkov
Igor Stojkov
FKFelicitas Kühne
Felicitas Kühne
MAMarjan Arvandi
Marjan Arvandi
SPSibylle Puntscher
Sibylle Puntscher
Nature‐based social prescribing (NBSP) is an evolving subject aiming to reduce loneliness and to foster social connections, health, and well‐being. To evaluate the short‐term and long‐term consequences of different health technologies, decision‐analytic modeling can be applied. Decision‐analytic modeling studies systematically integrate current short‐ and long‐term evidence to weigh benefits, harms, and costs of different strategies. Our systematic literature review identified and assessed decision‐analytic modeling studies addressing specifically NBSP or other interventions aiming to reduce loneliness. Predefined inclusion/exclusion criteria guided our systematic literature search in five databases. Title/abstract screening and full‐text screening were conducted by two independent reviewers. An a priori defined extraction table included country, intervention, and model type. The Philips framework was used to evaluate the quality of the studies. Overall, 3273 studies were identified, and 16 studies were eligible for full‐text screening. None of these studies applied a decision‐analytic model specifically to NBSP. However, two studies compared interventions for reducing loneliness. One study was conducted in Australia and performed a cost‐utility analysis, resulting in cost‐saving results and a positive return on investment. The second study was conducted in England and applied a cost‐effectiveness analysis resulting in 768 British pounds per loneliness‐free year gained. Overall, the evaluated interventions can be regarded as cost‐effective, and in some instances, they have the potential to save costs. Further research on the connection of loneliness, overall health, social well‐being, and quality of life and their integration into decision‐analytic studies is needed.

17 February 2023 in medRxiv
Verified
Preprint
Open access
PDF file
FKFelicitas Kühne
Felicitas Kühne
KAKatharina Achtert
Katharina Achtert
FPFranziska Pueschner
Franziska Pueschner
DUDominika Urbanski-Rini
Dominika Urbanski-Rini
JSJuliane Schiller
Juliane Schiller
ENErnestine Nahar
Ernestine Nahar
Objectives: Despite national recommendations for use of pneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugate vaccines (PCVs) with expanded coverage have the potential to reduce the pneumococcal disease burden among adults. Methods: Using a Markov model, we evaluated the lifetime outcomes/costs comparing 20-valent PCV (PCV20) with standard of care (SC) vaccination for prevention of CAP and IPD among adults aged ≥60 years and at-risk adults aged 18-59 years in Germany. PCV20 also was compared with sequential vaccination with 15-valent PCV (PCV15) followed by (→) PPSV23 in a scenario analysis. Results: Over the course of a lifetime (82 years), use of PCV20 vs. SC would prevent 54,333 hospitalizations, 26,368 outpatient CAP cases, 10,946 disease-related deaths yield 74,694 additional life-years (LYs), while lowering total medical costs by 363.2M €. PCV20 remained cost saving (i.e., dominant) versus SC even in numerous sensitivity analyses. In the scenario analysis, PCV20 also showed to be cost-saving compared to using PCV15→PPSV23. Conclusions: One dose of PCV20 among adults aged ≥60 years and adults aged 18-59 years with moderate- and high-risk conditions would substantially reduce pneumococcal disease, save lives, and be cost saving compared with SC. HIGHLIGHTS: Pneumococcal disease causes significant morbidity and mortality among adults in Germany New, higher valent vaccines have the potential to reduce disease burden and associated costs in vulnerable populations ver a lifetime, 20-valent pneumococcal conjugate vaccine was found to be cost-saving compared with current standard of care for pneumococcal disease prevention among adults in Germany

15 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ATAn Ta
An Ta
FKFelicitas Kühne
Felicitas Kühne
MLMaren Laurenz
Maren Laurenz
CEChristof von Eiff
Christof von Eiff
SWSophie Warren
Sophie Warren
JPJohnna Perdrizet
Johnna Perdrizet
Background: The 13-valent pneumococcal conjugate vaccine (PCV13) has been included by Germany’s Standing Committee on Vaccinations for infants since 2009, resulting in major reductions in pneumococcal disease (PD). Higher-valent vaccines may further reduce PD burden. This cost-effectiveness analysis compared PCV20 under 3+1 schedule with PCV15 and PCV13, both under 2+1 schedule, in Germany’s pediatric population. Methods: A Markov model with annual cycles over a 10-year time horizon was adapted to simulate the clinical and economic consequences to the German population and compare pediatric vaccination with PCV20 to lower-valent PCVs. The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for vaccine direct and indirect effect estimates. Epidemiologic, utility, and medical cost inputs were obtained from published sources. Benefits and costs were discounted at 3% from a German societal perspective. Outcomes included PD cases, deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results: In the base case, PCV20 provided greater health benefits than PCV13, averting more cases of invasive pneumococcal disease (IPD; 15,301), hospitalized and non-hospitalized pneumonia (460,197 and 472,365, respectively), otitis media (531,634), and 59,265 deaths over 10 years. This resulted in 904,854 additional QALYs and a total cost-saving of €2,393,263,611, making PCV20 a dominant strategy compared with PCV13. Compared to PCV15, PCV20 was estimated to avert an additional 11,334 IPD, 704,948 pneumonia, and 441,643 otitis media cases, as well as 41,596 deaths. PCV20 was associated with a higher QALY gain and lower cost (i.e., dominance) compared with PCV15. The robustness of the results was confirmed through scenario analyses as well as deterministic and probabilistic sensitivity analyses. Conclusion: PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over the model time horizon. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20’s broader serotype coverage. Key Summary Points: Streptococcus pneumoniae is the leading cause of bacterial pneumonia and global mortality in children. Pneumococcal conjugate vaccines (PCVs) elicit robust and durable immune responses in both pediatric and adult populations. This study examined the cost-effectiveness of PCV20 under a 3+1 schedule in Germany’s pediatric population compared with PCV13 and a secondary comparator (PCV15), both under a 2+1 schedule. PCV20 was estimated to prevent more pneumococcal disease cases and deaths versus PCV13 and PCV15, as well as providing greater quality-adjusted life years and cost savings (i.e., dominant strategy) over 10 years. Implementation of PCV20 under a 3+1 schedule into the German pediatric immunization program would result in greater clinical and economic benefits versus PCV13 and PCV15, both under a 2+1 schedule. Plain language summary: Pneumococcal diseases (e.g., ear infections, pneumonia, bloodstream infections) are among the leading causes of illness and death in children worldwide. The pneumococcal conjugate vaccine (PCV) protects against pneumococcal diseases and has significantly reduced the number of newly diagnosed cases. Higher-valent vaccines (which provide coverage for a greater number of disease-causing serotypes) have recently received EC approval for use in adults and EC approval for use in infants is expected soon. This study examined costs and health benefits associated with the 20-valent PCV (PCV20) under a 3+1 (i.e., three primary doses and one booster dose) schedule in Germany’s childhood vaccination program compared with 13-valent PCV (PCV13) and the 15-valent PCV (PCV15), both under a 2+1 (two primary doses, one booster) schedule. PCV20 was estimated to result in greater health benefits from avoiding more cases in pneumococcal diseases and lower costs compared with both PCV13 and PCV15. PCV20, therefore, is considered the best option among the three vaccines for children in Germany.

20 October 2021 in Medical Decision Making
Verified
Journal Article
Closed access
PDF file
FKFelicitas Kühne
Felicitas Kühne
URUrsula Rochau
Ursula Rochau
NPNoman Paracha
Noman Paracha
JYJennifer M. Yeh
Jennifer M. Yeh
ESEduardo Sabate
Eduardo Sabate
Uwe SiebertUwe Siebert
Uwe Siebert
Background: Bevacizumab is efficacious in delaying ovarian cancer progression and controlling ascites. The ICON7 trial showed a significant benefit in overall survival for bevacizumab, whereas the GOG-218 trial did not. GOG-218 allowed control group patients to switch to bevacizumab upon progression, which may have biased the results. Lack of data on switching behavior prevented the application of g-methods to adjust for switching. The objective of this study was to apply decision-analytic modeling to estimate the impact of switching bias on causal treatment-effect estimates. Methods: We developed a causal decision-analytic Markov model (CDAMM) to emulate the GOG-218 trial and estimate overall survival. CDAMM input parameters were based on data from randomized clinical trials and the published literature. Overall switching proportion was based on GOG-218 trial information, whereas the proportion switching with and without ascites was estimated using calibration. We estimated the counterfactual treatment effect that would have been observed had no switching occurred by denying switching in the CDAMM. Results: The survival curves generated by the CDAMM matched well with the ones reported in the GOG-218 trial. The survival curve correcting for switching showed an estimated bias such that 79% of the true treatment effect could not be observed in the GOG-218 trial. Results were most sensitive to changes in the proportion progressing with severe ascites and mortality. Limitations: We used a simplified model structure and based model parameters on published data and assumptions. Robustness of the CDAMM was tested and model assumptions transparently reported. Conclusions: Medical-decision science methods may be merged with empirical methods of causal inference to integrate data from other sources where empirical data are not sufficient. We recommend collecting sufficient information on switching behavior when switching cannot be avoided.

23 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JPJohnna Perdrizet
Johnna Perdrizet
DSDominik Schröder
Dominik Schröder
FKFelicitas Kühne
Felicitas Kühne
JSJulia Schiffner-Rohe
Julia Schiffner-Rohe
MLMaren Laurenz
Maren Laurenz
CEChristof von Eiff
Christof von Eiff
Introduction: Cost-effectiveness analysis (CEA) is crucial when evaluating the health and economic value of vaccines compared to the current standard of care (SoC) and provides essential information to assist decision-makers in maximizing health gains when allocating resources. The design of the CEA should address the specific policy questions, disease area, vaccine characteristics, and consider all relevant vaccination effects on the population. Areas covered: We presented a case study on the CEA of pneumococcal conjugate vaccines (PCVs) in infants in Germany using a closed single cohort-based approach versus a population-based approach. Except for the design of the modelled population/cohort, all other inputs and characteristics were kept identical in the cost-effectiveness model. We contrasted model results, inferences, and conclusions between both design approaches. Expert Opinion: CEA must carefully consider the included population in the analysis based on their specific policy questions and the characteristics of the vaccine being evaluated. The choice between population-based and closed single-cohort models fundamentally depends on whether the vaccine affects disease transmission dynamics. Population models are essential for vaccines that disrupt transmission patterns across population groups, such as PCVs in infants, while closed single-cohort models are suitable for vaccines impacting only vaccinated individuals without affecting disease transmission. Article highlights: Identifying the appropriate model design is crucial for conducting cost-effectiveness analyses (CEAs) of vaccines, particularly when addressing vaccine technical committee (VTC) policy questions, which aim to optimize individual and population health benefits. Closed single cohort-based designs track a group of individuals, while population-based designs evaluate an entire cross-sectional population, making the choice between the two designs vital when vaccines have secondary, indirect effects. We presented a case study comparing PCV20 with PCV13 and PCV15 in infants in Germany using a closed single cohort-based approach and a population-based approach. Modelled results highlighted that the closed single cohort-based approach substantially underestimated public health benefits and economic advantages associated with PCV20, whereas the population-based approach demonstrated PCV20 as cost-saving strategy while offering superior health outcomes, indicating it as a dominant vaccination option when accounting for Germany’s entire population. Selecting an inappropriate model design for CEAs of vaccines could result in unintended consequences, such as adversely affecting national recommendations, policies, and programs, leading to suboptimal decision-making for population health. Researchers and policymakers must carefully select appropriate population frameworks and adhere to methodological guidelines to ensure accurate inferences in vaccine economic evaluations.